There is substantial evidence of the elevated risk of cancer among individuals with type 2 diabetes. Very little is known, however, about the role that antidiabetic therapies play in this relationship. The objective of this program of research was to examine whether there is a therapeutic risk associated with antidiabetic therapies that increase circulating insulin levels, such as sulfonylureas and exogenous insulin, or a therapeutic benefit associated with antidiabetic therapies that reduce insulin resistance, such as metformin and the glitazones. This objective was achieved through four related population-based cohort studies using the administrative databases from Saskatchewan Health. The first study looked at the effect of the older antidiabetic therapies metformin and sulfonylureas on cancer mortality. The focus of the second study was to explore more closely the effect of metformin and sulfonylurea by using a time-varying Cox regression to define drug exposures. The third study looked more closely at the effect of exogenous insulin therapy and cancer mortality, and the last study focused on the more recently available antidiabetic therapy the glitazones and cancer mortality.
We found that individuals with type 2 diabetes exposed to sulfonylurea monotherapy had a significantly increased risk of cancer-related mortality, compared to patients exposed to metformin. We also observed a dose-response gradient with exogenous insulin therapy and cancer mortality, whereby individuals exposed to higher levels of insulin had a higher risk of cancer mortality. In the last study, we found that the newer class of antidiabetic therapies, the glitazones, were associated with a decreased risk of cancer mortality.
These finding add further support that antidiabetic therapies may play a moderating role in the relationship between type 2 diabetes and cancer outcomes. However, it is unclear whether the increased risk of cancer mortality we observed was related to a toxic effect of sulfonylureas and exogenous insulin or a protective effect of metformin and glitazones, or due to some unmeasured effect related to both choice of drug therapy and cancer risk. Future research should incorporate a non-diabetes control cohort for comparison and examine the more proximal outcome measure cancer incidence. / Epidemiology
| Identifer | oai:union.ndltd.org:LACETR/oai:collectionscanada.gc.ca:AEU.10048/639 |
| Date | 11 1900 |
| Creators | Bowker, Samantha Lyndsey |
| Contributors | Johnson, Jeff (Department of Public Health Sciences, University of Alberta), Yasui, Yutaka (Department of Public Health Sciences, University of Alberta), Veugelers, Paul (Department of Public Health Sciences, University of Alberta), Johnson, Jeff (Department of Public Health Sciences, University of Alberta), Yasui, Yutaka (Department of Public Health Sciences, University of Alberta), Veugelers, Paul (Department of Public Health Sciences, University of Alberta), Lynd, Larry (Faculty of Pharmaceutical Sciences, University of British Columbia), Voaklander, Don (Department of Public Health Sciences, University of Alberta), Brancati, Fredrick (School of Medicine, Johns Hopkins University) |
| Source Sets | Library and Archives Canada ETDs Repository / Centre d'archives des thèses électroniques de Bibliothèque et Archives Canada |
| Language | English |
| Detected Language | English |
| Type | Thesis |
| Format | 763914 bytes, application/pdf |
| Relation | Bowker SL. Diabetes Care 2006. 29: 254-8. |
Page generated in 0.0019 seconds